Your browser is no longer supported. Please, upgrade your browser.
VRTX Vertex Pharmaceuticals Incorporated weekly Stock Chart
VRTX [NASD]
Vertex Pharmaceuticals Incorporated
IndexS&P 500 P/E102.03 EPS (ttm)2.25 Insider Own0.10% Shs Outstand256.95M Perf Week-2.73%
Market Cap58.86B Forward P/E34.12 EPS next Y6.71 Insider Trans-70.68% Shs Float256.80M Perf Month4.13%
Income583.80M PEG3.44 EPS next Q1.20 Inst Own98.70% Short Float1.40% Perf Quarter20.24%
Sales3.62B P/S16.26 EPS this Y99.10% Inst Trans0.08% Short Ratio2.68 Perf Half Y35.09%
Book/sh20.45 P/B11.20 EPS next Y39.33% ROA31.40% Target Price242.68 Perf Year22.77%
Cash/sh15.55 P/C14.73 EPS next 5Y29.64% ROE44.00% 52W Range163.68 - 237.47 Perf YTD4.62%
Dividend- P/FCF43.17 EPS past 5Y23.90% ROI11.20% 52W High-3.54% Beta1.46
Dividend %- Quick Ratio3.30 Sales past 5Y20.30% Gross Margin86.60% 52W Low39.94% ATR4.34
Employees2500 Current Ratio3.40 Sales Q/Q21.10% Oper. Margin21.40% RSI (14)53.85 Volatility1.89% 1.98%
OptionableYes Debt/Eq0.11 EPS Q/Q-55.40% Profit Margin59.20% Rel Volume0.67 Prev Close233.91
ShortableYes LT Debt/Eq0.10 EarningsFeb 04 AMC Payout0.00% Avg Volume1.34M Price229.06
Recom1.90 SMA200.92% SMA503.64% SMA20021.82% Volume900,076 Change-2.07%
Nov-19-19Upgrade Guggenheim Neutral → Buy $252
Nov-12-19Initiated SunTrust Buy $235
Oct-17-19Resumed BofA/Merrill Buy $220
Sep-03-19Upgrade Goldman Neutral → Buy $226 → $254
Aug-01-19Downgrade Needham Buy → Hold
May-23-19Resumed Citigroup Buy $205
May-21-19Initiated Credit Suisse Outperform $209
Apr-12-19Initiated Evercore ISI In-line
Mar-26-19Upgrade William Blair Mkt Perform → Outperform
Mar-19-19Downgrade SVB Leerink Outperform → Mkt Perform
Feb-06-19Downgrade Maxim Group Buy → Hold
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Oct-26-18Upgrade H.C. Wainwright Neutral → Buy $220
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Aug-07-18Reiterated Stifel Buy $182 → $200
Mar-05-18Reiterated Maxim Group Buy $195 → $200
Feb-13-18Reiterated JMP Securities Mkt Outperform $200 → $211
Feb-01-18Reiterated Barclays Overweight $180 → $200
Jan-05-18Upgrade BofA/Merrill Neutral → Buy
Oct-18-17Reiterated RBC Capital Mkts Outperform $175 → $181
Jan-23-20 05:50PM  Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know Zacks
12:31PM  Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: Should You Buy? Zacks
12:10PM  Why Vertex (VRTX) is Poised to Beat Earnings Estimates Again Zacks
11:13AM  If You Had Bought Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Three Years Ago, You Could Pocket A 175% Gain Today Simply Wall St.
Jan-22-20 01:01AM  Rally Pauses as Coronavirus Spreads to U.S. Zacks
Jan-21-20 04:30PM  Why This Top-Notch Biotech Stock Just Plunged By Double Digits Investor's Business Daily
04:01PM  Vertex to Announce Full-Year and Fourth-Quarter 2019 Financial Results on January 30 Business Wire
02:50PM  Mass. employers earn high marks in LGBTQ-friendly workplace index American City Business Journals
Jan-14-20 03:56PM  These 3 Momentum Stocks Have Room for Further Upside, Says Jefferies TipRanks
Jan-13-20 05:50PM  Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know Zacks
09:25AM  Vertex Tests Buy Point Investor's Business Daily Video
Jan-11-20 08:00AM  These Four Stocks Are In Buy Range Before Key Healthcare Conference Investor's Business Daily
Jan-10-20 02:20PM  Cambridge startup raises $110M for re-doseable gene therapies American City Business Journals
08:52AM  A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations Benzinga
Jan-09-20 08:13PM  As Tesla Stock Dances To New Highs, This Could Be The Next Proper Buy Point Investor's Business Daily
09:31AM  Thinking about trading options or stock in Electronic Arts, Tesla, UnitedHealth Group, Vertex Pharmaceuticals, or Workday? PR Newswire
08:08AM  Dow Jones Futures: Stock Market Rally Refuses To 'Stand Down'; Netflix, Vertex, Lululemon Clear Buy Points Investor's Business Daily
Jan-08-20 04:46PM  This IBD Stock Of The Day Is A Rarity Among Biotechs And It's Breaking Out Investor's Business Daily
04:01PM  Vertex to Present at the J.P. Morgan Healthcare Conference on January 13 Business Wire
08:57AM  Vertex Pharmaceuticals Stock Is Undervalued, Analyst Says Barrons.com
Jan-07-20 05:45PM  Vertex Pharmaceuticals (VRTX) Stock Moves -0.11%: What You Should Know Zacks
05:00AM  Top Picks 2020- Vertex Pharmaceuticals VRTX MoneyShow
Jan-06-20 03:11PM  These Are The 5 Best Stocks To Buy And Watch Now Investor's Business Daily
07:17AM  10 Stocks With the Highest Sales Growth in 2020 According to Goldman Investopedia
Jan-02-20 08:00AM  Biotech Stocks Are On Fire Who's Leading The Profit Pack For 2020? Investor's Business Daily
Dec-31-19 05:50PM  Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know Zacks
09:58AM  Dow Jones Today, Stocks Mixed As Trump Sets China Trade Deal Date, 3 Blue Chips In Buy Range Investor's Business Daily
08:25AM  The Zacks Analyst Blog Highlights: Medtronic, United Technologies, Union Pacific, Vertex Pharmaceuticals and NextEra Energy Zacks
Dec-30-19 02:34PM  Top Research Reports for Medtronic, United Technologies & Union Pacific Zacks
Dec-29-19 09:40PM  Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus Benzinga
Dec-27-19 09:39AM  The top-read BBJ stories of 2019 American City Business Journals
09:30AM  Vertex Shows Flat Action Investor's Business Daily Video
Dec-25-19 06:15PM  Vertex Pharmaceuticals Incorporated (VRTX) vs. Hedge Fund Favorites in 2019 Insider Monkey
Dec-24-19 12:38PM  Is Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) A High Quality Stock To Own? Simply Wall St.
12:15PM  Biotech Leading in Q4: Best ETFs & Stocks Zacks
07:30AM  10 Biotech M&A Targets Under The Scanner For 2020 Benzinga
Dec-23-19 05:50PM  Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know Zacks
Dec-20-19 11:30AM  Is Vertex Pharmaceuticals (VRTX) Stock Outpacing Its Medical Peers This Year? Zacks
08:13AM  New Strong Buy Stocks for December 20th Zacks
Dec-19-19 05:45PM  3 Tech Stocks for Growth Investors to Buy for 2020 Zacks
10:18AM  Biotech Stock Outlook: M&A Activity Retains Growth Streak Zacks
07:05AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Dec-17-19 05:45PM  Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know Zacks
Dec-16-19 07:05AM  New Strong Buy Stocks for December 16th Zacks
Dec-13-19 01:55PM  Vertex and Republic of Ireland Expand Long-Term Cystic Fibrosis Medicines Reimbursement Agreement to Include Triple Combination Therapy for All Eligible Patients Ages 12 and Over Once Licensed Business Wire
Dec-12-19 02:37PM  Stocks Hit Records on China Trade Hope & Buy this Biotech Stock - Free Lunch Zacks
10:53AM  New Strong Buy Stocks for December 12th Zacks
Dec-11-19 02:42PM  Vertex's Kalydeco Gets EU Approval to Treat CF in Infants Zacks
12:45PM  Looking for a Growth Stock? 3 Reasons Why Vertex (VRTX) is a Solid Choice Zacks
09:41AM  Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar Zacks
07:24AM  The Zacks Analyst Blog Highlights: Spark Energy, Vertex, ResMed, Prologis and Boston Beer Zacks
Dec-10-19 08:09AM  5 Defensive Stocks to Buy as Volatility Index Soars Zacks
06:57AM  Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) in Infants With Cystic Fibrosis Ages 6 Months to Less Than 12 Months With Certain Mutations in the CFTR Gene Business Wire
Dec-09-19 09:55AM  Blueprint's (BPMC) Systemic Mastocytosis Study Data Impresses Zacks
09:52AM  Gilead (GILD) Announces Positive Long-Term Data on Yescarta Zacks
Dec-06-19 07:00AM  Three Stocks from the Zacks #1 Rank Uptrends Screen Zacks
Dec-05-19 03:53PM  Spero Posts Preliminary Data on SPR720 for Pulmonary Disease Zacks
03:49AM  Gene Therapy the Next Best Thing: Here's Why (Revised) Zacks
Dec-04-19 10:25AM  Biogen's Lupus Candidate Meets Endpoint in Phase II Study Zacks
09:42AM  Gene Therapy the Next Best Thing: Here's Why Zacks
Dec-03-19 10:45AM  Seattle Genetics, Astellas Tie Up With Merck for Cancer Study Zacks
08:59AM  Puma Biotech Expands Pierre Fabre License to Add Countries Zacks
Dec-02-19 11:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
10:22AM  Acorda (ACOR) Down More Than 80% Year to Date: Here's Why Zacks
09:09AM  In the money Dec. 2: $49M reported raised American City Business Journals
Nov-29-19 12:15PM  Biotech Tops in November: Best ETFs & Stocks Zacks
Nov-28-19 07:02PM  Hedge Funds Are Warming Up To Vertex Pharmaceuticals Incorporated (VRTX) Insider Monkey
08:10AM  Incyte's NDA for Pemigatinib Gets FDA's Priority Review Tag Zacks
Nov-27-19 08:24AM  The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion Zacks
06:52AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Nov-26-19 07:06PM  Why Biotech ETFs Surged in Monday's Trading Session Zacks
10:50AM  Vertex Pharma Shares Are Surging with Huge Demand Investopedia
06:07AM  4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal Zacks
Nov-25-19 06:55PM  Genomics ETFs Surge on CRISPR's Gene Editing Progress Zacks
10:06AM  Biotech Stocks Awaken From Long Slumber Investopedia
Nov-22-19 09:43AM  Amgen (AMGN) Completes Otezla Buyout, Raises 2019 Guidance Zacks
Nov-21-19 10:24AM  Vertex (VRTX) Gets French Reimbursement for CF Drug Orkambi Zacks
08:00AM  Vertex Pharmaceuticals Shares March Higher, Can It Continue? Zacks
Nov-20-19 10:45AM  Crispr Therapeutics Rises After Company Announces Stock Sale Barrons.com
09:50AM  The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Vertex Pharmaceuticals, Incyte and Regeneron Pharmaceuticals Zacks
09:31AM  Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More Zacks
09:12AM  Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data Zacks
07:25AM  The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data Benzinga
05:00AM  French Authorities Approve National Reimbursement of ORKAMBI (lumacaftor/ivacaftor) for Eligible People Ages Two and Older With Cystic Fibrosis Business Wire
Nov-19-19 05:20PM  Biotech Stock Pops On Promising First In-Human CRISPR Gene-Editing Drug Investor's Business Daily
04:28PM  Biotech Stock Pops On Promising First In-Human CRISPR Gene-Editing Drug Investor's Business Daily
11:40AM  Crispr's Gene-Editing Therapy Found Effective In Treating Blood Disorders In Early-Stage Study Benzinga
11:25AM  Crispr Therapeutics Stock Spikes on Positive Gene-Editing Results Barrons.com
10:46AM  CRISPR Therapeutics stock jumps on early gene editing data American City Business Journals
10:14AM  4 Big Biotech Stocks Worth Considering Post Q3 Earnings Zacks
07:00AM  CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies GlobeNewswire
Nov-15-19 10:20AM  Earnings Estimates Rising for Vertex (VRTX): Will It Gain? Zacks
05:38AM  Vertex Pharmaceuticals: The 'Endpoint' Is a Bullish Golden Cross TheStreet.com
Nov-14-19 05:14PM  US Market Mostly Lower Thursday GuruFocus.com
Nov-13-19 02:32PM  Ex-Novartis exec named as Flagship's matchmaker for Big Pharma partnerships American City Business Journals
07:55AM  UPDATE 1-Vertex deal with Wales expands cystic fibrosis treatment coverage to all of UK Reuters
07:08AM  Vertex reaches deal with Wales for cystic fibrosis treatment Reuters
06:29AM  Vertex Confirms Wales Offer Accepted for Access to All Licensed Cystic Fibrosis Medicines Business Wire
Nov-12-19 10:56AM  FDA intervenes for 3rd time in Solid Biosciences' Duchenne drug tests American City Business Journals
10:51AM  Vertex Confirms Northern Ireland Offer Accepted for Cystic Fibrosis Medicines Business Wire
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna Therapeutics, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; and Molecular Templates, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Parini MichaelEVP, CL&AOJan 22Option Exercise187.53118835,004Jan 24 04:10 PM
Parini MichaelEVP, CL&AOJan 22Sale237.50123835,003Jan 24 04:10 PM
Sachdev AmitEVP, Chief Patient OfficerJan 16Option Exercise109.145,000545,70041,190Jan 21 04:14 PM
Sachdev AmitEVP, Chief Patient OfficerJan 16Sale235.005,0001,175,00036,190Jan 21 04:14 PM
Parini MichaelEVP, CL&AOJan 13Option Exercise90.292,125191,86637,128Jan 15 04:08 PM
Silva Paul MSVP & ControllerJan 13Option Exercise90.2986077,64918,619Jan 15 04:09 PM
Parini MichaelEVP, CL&AOJan 13Sale226.782,125481,91135,003Jan 15 04:08 PM
Silva Paul MSVP & ControllerJan 13Sale229.38860197,26717,759Jan 15 04:09 PM
Sachdev AmitEVP, Chief Patient OfficerJan 08Option Exercise109.145,000545,70041,190Jan 10 04:46 PM
Tatsis OuraniaSVP, CROJan 08Option Exercise187.531,675314,1138,927Jan 10 04:22 PM
Silva Paul MSVP & ControllerJan 08Option Exercise131.8913,7501,813,48831,509Jan 10 04:32 PM
Sachdev AmitEVP, Chief Patient OfficerJan 08Sale230.005,0001,150,00036,190Jan 10 04:46 PM
Tatsis OuraniaSVP, CROJan 08Sale227.531,675381,1137,252Jan 10 04:22 PM
Silva Paul MSVP & ControllerJan 08Sale231.8913,7503,188,48817,759Jan 10 04:32 PM
Parini MichaelEVP, CL&AOJan 06Option Exercise122.454,250520,41339,253Jan 08 04:11 PM
Parini MichaelEVP, CL&AOJan 06Sale222.004,250943,51435,003Jan 08 04:11 PM
Silva Paul MSVP & ControllerJan 02Option Exercise102.3725,6302,623,81043,389Jan 06 04:17 PM
YOUNG WILLIAM DDirectorJan 02Option Exercise72.1420,0001,442,80029,311Jan 06 04:18 PM
Silva Paul MSVP & ControllerJan 02Sale218.9225,6305,610,99317,759Jan 06 04:17 PM
YOUNG WILLIAM DDirectorJan 02Sale218.9320,0004,378,6969,311Jan 06 04:18 PM
YOUNG WILLIAM DDirectorDec 30Option Exercise65.6530,0001,969,50039,311Jan 02 04:21 PM
YOUNG WILLIAM DDirectorDec 30Sale218.7630,0006,562,7159,311Jan 02 04:21 PM
Sachdev AmitEVP, Chief Patient OfficerDec 09Option Exercise109.145,000545,70038,416Dec 10 04:49 PM
Sachdev AmitEVP, Chief Patient OfficerDec 09Sale225.005,0001,125,00033,416Dec 10 04:49 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 25Option Exercise187.533,910733,24235,463Nov 26 04:11 PM
Kewalramani ReshmaEVP and CMONov 25Option Exercise187.534,692879,89117,790Nov 26 04:12 PM
Sachdev AmitEVP, Chief Patient OfficerNov 25Option Exercise109.145,000545,70038,416Nov 26 04:13 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 25Sale219.373,910857,73731,553Nov 26 04:11 PM
Kewalramani ReshmaEVP and CMONov 25Sale219.374,6921,029,28413,098Nov 26 04:12 PM
Sachdev AmitEVP, Chief Patient OfficerNov 25Sale220.005,0001,100,00033,416Nov 26 04:13 PM
Sachdev AmitEVP, Chief Patient OfficerNov 19Option Exercise109.145,000545,70038,416Nov 21 04:19 PM
LEIDEN JEFFREY MCEO & PresidentNov 19Option Exercise116.8096,53411,275,141202,880Nov 21 04:21 PM
Sachdev AmitEVP, Chief Patient OfficerNov 19Sale215.005,0001,075,00033,416Nov 21 04:19 PM
LEIDEN JEFFREY MCEO & PresidentNov 19Sale210.9196,53420,360,052106,346Nov 21 04:21 PM
LEIDEN JEFFREY MCEO & PresidentNov 18Option Exercise116.804,434517,893109,287Nov 19 04:12 PM
LEIDEN JEFFREY MCEO & PresidentNov 18Sale210.004,434931,140106,346Nov 19 04:12 PM
LEIDEN JEFFREY MCEO & PresidentNov 15Option Exercise116.805,000583,988109,663Nov 19 04:12 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 15Sale205.956012,35731,553Nov 19 04:07 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 15Sale205.95193,91333,240Nov 19 04:09 PM
Kewalramani ReshmaEVP and CMONov 15Sale205.956112,56313,098Nov 19 04:11 PM
LEIDEN JEFFREY MCEO & PresidentNov 15Sale210.005,0001,050,000106,346Nov 19 04:12 PM
Parini MichaelEVP, CL&AONov 15Sale205.958417,30035,003Nov 19 04:15 PM
Sachdev AmitEVP, Chief Patient OfficerNov 15Sale205.955711,73933,416Nov 19 04:16 PM
Tatsis OuraniaSVP, CRONov 15Sale205.9551,0307,252Nov 19 04:17 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 13Option Exercise155.578,5601,331,67941,800Nov 15 04:03 PM
Parini MichaelEVP, CL&AONov 13Option Exercise155.574,892761,04839,895Nov 15 04:05 PM
Tatsis OuraniaSVP, CRONov 13Option Exercise155.572,853443,84110,105Nov 15 04:07 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 13Sale205.578,5601,759,67933,240Nov 15 04:03 PM
Parini MichaelEVP, CL&AONov 13Sale205.504,8921,005,30635,003Nov 15 04:05 PM
Tatsis OuraniaSVP, CRONov 13Sale205.592,853586,5487,252Nov 15 04:07 PM
Kewalramani ReshmaEVP and CMONov 08Option Exercise155.5750979,18513,607Nov 13 04:08 PM
Kewalramani ReshmaEVP and CMONov 08Sale199.00509101,29113,098Nov 13 04:08 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 06Option Exercise155.571,223190,26232,776Nov 07 04:36 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 06Sale197.211,223241,18931,553Nov 07 04:36 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 04Option Exercise88.494,126365,11735,679Nov 06 04:10 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 04Option Exercise89.153,708330,57835,395Nov 06 04:11 PM
Parini MichaelEVP, CL&AONov 04Option Exercise86.522,330201,59237,333Nov 06 04:13 PM
Sachdev AmitEVP, Chief Patient OfficerNov 04Option Exercise88.904,097364,23537,513Nov 06 04:15 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 04Sale201.623,708747,60733,240Nov 06 04:11 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 04Sale200.454,126827,04931,553Nov 06 04:10 PM
Parini MichaelEVP, CL&AONov 04Sale200.502,330467,16835,003Nov 06 04:13 PM
Sachdev AmitEVP, Chief Patient OfficerNov 04Sale200.344,097820,79533,416Nov 06 04:15 PM
Bhatia Sangeeta N.DirectorNov 01Option Exercise152.741,291197,1876,540Nov 04 04:11 PM
Kearney Terrence CDirectorNov 01Option Exercise79.1747,4483,756,36725,811Nov 04 04:15 PM
LEIDEN JEFFREY MCEO & PresidentNov 01Option Exercise115.3796,82211,170,756176,577Nov 04 04:13 PM
LEIDEN JEFFREY MCEO & PresidentNov 01Sale200.0296,82219,365,992106,287Nov 04 04:13 PM
Kearney Terrence CDirectorNov 01Sale200.0050,60710,121,4005,811Nov 04 04:15 PM
Bhatia Sangeeta N.DirectorNov 01Sale200.001,291258,2005,249Nov 04 04:11 PM
LEIDEN JEFFREY MCEO & PresidentOct 31Option Exercise131.898,8791,171,051115,166Nov 04 04:13 PM
LEIDEN JEFFREY MCEO & PresidentOct 31Sale200.008,8791,775,800106,287Nov 04 04:13 PM
Kearney Terrence CDirectorOct 31Sale200.001,841368,2008,970Nov 04 04:15 PM
Kewalramani ReshmaEVP and CMOOct 30Option Exercise155.573,057475,57716,155Oct 31 04:36 PM
Kewalramani ReshmaEVP and CMOOct 30Sale199.003,057608,34313,098Oct 31 04:36 PM
Sachdev AmitEVP, Chief Patient OfficerOct 25Option Exercise91.054,311392,51737,727Oct 29 04:54 PM
Sachdev AmitEVP, Chief Patient OfficerOct 25Sale195.014,311840,68833,416Oct 29 04:54 PM
ALTSHULER DAVIDEVP, Global Research and CSOOct 22Option Exercise155.573,669570,78635,222Oct 24 07:13 PM
LEIDEN JEFFREY MCEO & PresidentOct 22Option Exercise116.61107,83112,574,276178,707Oct 24 07:23 PM
MCGLYNN MARGARET GDirectorOct 22Option Exercise72.1420,0001,442,80024,124Oct 24 07:26 PM
Sachdev AmitEVP, Chief Patient OfficerOct 22Option Exercise86.523,883335,95737,299Oct 24 07:28 PM
Sachdev AmitEVP, Chief Patient OfficerOct 22Sale190.273,883738,81833,416Oct 24 07:28 PM
MCGLYNN MARGARET GDirectorOct 22Sale190.0020,0003,800,0004,124Oct 24 07:26 PM
LEIDEN JEFFREY MCEO & PresidentOct 22Sale190.00107,83120,487,890106,287Oct 24 07:23 PM
Kewalramani ReshmaEVP and CMOOct 22Sale189.00638120,58213,098Oct 24 07:18 PM
ALTSHULER DAVIDEVP, Global Research and CSOOct 22Sale194.373,669713,14431,553Oct 24 07:13 PM
Parini MichaelEVP, CL&AOOct 17Option Exercise122.454,250520,41339,253Oct 21 04:29 PM
Parini MichaelEVP, CL&AOOct 17Sale177.804,250755,65035,003Oct 21 04:29 PM
Parini MichaelEVP, CL&AOOct 14Option Exercise90.292,125191,86637,128Oct 16 04:14 PM
Parini MichaelEVP, CL&AOOct 14Sale174.062,125369,88535,003Oct 16 04:14 PM
Bhatia Sangeeta N.DirectorOct 02Option Exercise126.517,088896,67613,628Oct 04 04:11 PM
Bhatia Sangeeta N.DirectorOct 02Sale166.808,3791,397,6405,249Oct 04 04:11 PM
Tatsis OuraniaSVP, CROOct 02Sale167.6944474,4547,252Oct 03 04:25 PM
Tatsis OuraniaSVP, CROOct 01Sale169.1118831,7937,696Oct 03 04:25 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 19Option Exercise103.2512,5011,290,68136,212Aug 20 04:30 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 19Sale186.3812,5012,329,97631,553Aug 20 04:30 PM
MCGLYNN MARGARET GDirectorAug 13Option Exercise81.5410,000815,40014,124Aug 15 04:11 PM
MCGLYNN MARGARET GDirectorAug 13Sale185.0010,0001,850,0004,124Aug 15 04:11 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 08Option Exercise131.892,125280,26635,365Aug 12 04:14 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 08Sale181.892,125386,51633,240Aug 12 04:14 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 05Option Exercise86.521,553134,36633,793Aug 06 04:41 PM
Parini MichaelEVP, CL&AOAug 05Option Exercise86.522,330201,59237,333Aug 06 04:43 PM